News

In a 58-week open-label extension, most patients with Parkinson disease treated with tavapadon avoided starting levodopa or required no dose increases, suggesting a potential levodopa-sparing effect.

A phase 3, double-blind study is assessing telitacicept in generalized myasthenia gravis, following prior trials that demonstrated substantial improvements in functional and strength-based clinical outcomes.

Data from the phase 2 Vibrance-1 trial showed that alixorexton was associated with improvements in patient-reported outcomes in adults with narcolepsy type 1 over up to 12 to 13 weeks of follow-up.

Neurology News Network for the week ending April 18, 2026. [WATCH TIME: 5 minutes]

A living systematic review presented at AAN 2026 showed that GLP-1 receptor agonists demonstrated biomarker and real-world signals of neuroprotection in Alzheimer disease.

Jaime Imitola, MD, FAAN, FANA, professor of neurology and director of the UConn Comprehensive MS Center, discussed validation data on VISIBL-MS and its role in improving early MS recognition.

The senior global medical director at Sanofi discussed the ongoing burden of CIDP, highlighting diagnostic challenges, treatment gaps, and the need for improved biomarkers and emerging therapies. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Semaglutide shows CNS biomarker shifts in early Alzheimer disease, lowering CSF tau and neurogranin while reshaping immune signals, as per new AAN data report.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric strokes!

A recently presented analysis at AAN 2026 reported comparable safety and tolerability between atogepant and erenumab, with atogepant demonstrating a greater likelihood of early response at 1 month in adults with migraine.

Real-world data of the ELEVATE-PD study, presented at AAN 2026, suggest that switching to IPX203 from other levodopa-based therapies may improve motor function in patients with Parkinson disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 17, 2026.

Single-dose adjunctive dexamethasone did not significantly lower 48-hour relapse rates or improve functional outcomes in children and adolescents treated for acute migraine in the emergency department.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Julie Kurek, MD. [LISTEN TIME: 25 minutes]

Paul George, MD, PhD, FAAN, a board member of the American Academy of Neurology (AAN), gave an inside look at what clinicians can expect from the upcoming AAN Annual Meeting, held April 18-22 in Chicago.

Findings from the phase 3 OCEANIC-STROKE study showed that the addition of asundexian, a factor XIa inhibitor, with antiplatelet therapy lowered recurrent ischemic stroke compared with placebo.

An exploratory analysis of a phase 3 trial showed that solriamfetol improved daytime wakefulness without producing consistent or clinically meaningful changes in nocturnal sleep quality measures.

Experts Laura Saucier, MD, MSc, and Jonathan Santoro, MD, examined pediatric MOGAD phenotypes, highlighting how variability in clinical presentation may influence treatment responses and inform individualized care strategies.

The FDA has cleared an updated Cala kIQ Plus wearable system, adding adaptive features to support personalized management of hand tremor in essential tremor and Parkinson disease.

In honor of International Pompe Day, held April 15, 2026, NeurologyLive reviewed recent studies on the latest research and evolving standards of care for Pompe disease.

International Pompe Day highlights advances in molecular diagnostics, newborn screening, and enzyme replacement therapy that have reshaped the recognition and management of Pompe disease over the past century.

In observance of International Pompe Day, held annually on April 15, catch up on the past year’s news and expert insights related to this rare disease.

Erika Trovato, DO, MS, associate chief medical officer at Burke Rehabilitation Hospital in New York, discusses interdisciplinary rehabilitation, emerging technologies, and the evolving focus on long-term outcomes and caregiver support in brain injury care.

The director of neurointerventional surgery at Abbott Northwestern Hospital, part of Allina Health, discussed evolving stroke care, patient selection, and emerging neurointerventional technologies shaping clinical practice.

The approved neurofilament light chain test offers a minimally invasive approach to assessing neuroaxonal damage, with potential to complement MRI in routine multiple sclerosis care.

A recent study revealed that a substantial proportion of patients with NMOSD required escalation from first-line immunosuppressants to rituximab, with baseline severe disability emerging as a key associated factor.

The medical director of neurointerventional surgery at Allina Health Brain and Spine Institute provided clinical insights on the procedural factors that guide patient selection for endovascular stroke intervention. [WATCH TIME: 3 minutes]